Why Medtronic Is One of the Smartest Companies on the Planet

Medtronic was just named one of the "smartest" companies on the planet by MIT Tech Review. Here are three reasons we agree.

Apr 19, 2014 at 10:00AM

MIT Tech Review recently named Medtronic (NYSE:MDT) one of of the 50 smartest companies of 2013, placing the 65-year-old medical device company side by side with much younger companies like Google (NASDAQ: GOOG), and SpaceX. Medtronic's industry rivals Boston Scientific (NYSE:BSX) and St. Jude Medical (NYSE:STJ) failed to make the cut.

MIT Tech Review offered a simple reason for its admiration of Medtronic: the fact that it continues to reduce the size of life-saving implantable devices.

The report cited Medtronic's 2 gram pacemaker, the tiniest in the world, as its top example. That pacemaker, which is the size of a Tic-Tac, is even smaller than St. Jude Medical's battery-sized pacemaker, which it acquired by buying Nanostim last October. Both Medtronic and St. Jude's pacemakers are implanted without open chest surgery through the femoral artery in the thigh.


Medtronic's history of miniaturizating pacemakers. Source: Medtronic.

However, Medtronic's tiny pacemaker is only one of several life-changing medical devices from the company. Let's take a look at three more reasons Medtronic should be considered one of the smartest medical device companies on the planet.

Connected pacemakers
Long before Medtronic was shrinking pacemakers down to the size of Tic-Tacs, it was helping doctors remotely monitor patients' pacemakers.

The idea was simple -- a patient at home holds a device (Medtronic's CareLink Home Monitor) up to the chest for a pacemaker reading, and a diagnostic report is sent via a telephone line to the physician's office.

Medtronic launched the CareLink system in 2005, building upon the remote monitoring technologies introduced by Biotronik in 2001. Over time, Medtronic's CareLink network evolved into an Internet-based service, which connects to a patient's EHRs (electronic health records). St. Jude Medical followed suit with a similar system (Merlin@home) in 2008, as did Boston Scientific (Latitude) in 2009.

Medtronic's CareLink inspired those industry peers to take the next step and develop pacemakers that could continuously report diagnostic data over wireless connections. St. Jude Medical eventually won that race, releasing a Wi-Fi pacemaker known as the Accent in 2009, although Medtronic and Boston Scientific followed shortly afterwards.

Medtronic, St. Jude Medical, and Boston Scientific all hope that these innovations can eventually boost sales for their cardiac rhythm management businesses -- all of which are very slow growth businesses:


Cardiac rhythm management revenue (most recent quarter)

YOY growth

% of total revenue


$1.18 billion



St. Jude Medical

$687 billion



Boston Scientific

$468 million



Source: Company quarterly reports.

A pacemaker for the brain
We generally associate pacemakers with the heart, but what about the brain?

Activa Pc Banner

Source: Medtronic

Medtronic recently developed a "smart" brain pacemaker -- known as the Activa PC -- which can record neural activity while simultaneously delivering an electrical current to stimulate the brain. The device was implanted in the first patients worldwide last August.

The concept of deep-brain stimulation with electricity isn't new -- it's been used in the past to treat patients with neurological disorders such as Parkinson's disease, depression, and epilepsy. However, most devices are one-way stimulators that have to be preset by specialists to treat certain conditions. St. Jude markets one such implantable device, which was approved in 2009 in Europe to treat Parkinson's disease.

In most cases, these devices can only be programmed to monitor the brain for a single purpose. For example, a brain stimulator designed to block seizures could only kick in upon detecting an incoming seizure.

By comparison, Medtronic's Activa PC+S DBS reads neural activity continuously to adjust the stimulation of the brain in a closed loop. The device can also be used to remotely monitor and study the neurological changes associated with harder-to-detect conditions such as depression.

A wearable artificial pancreas
That idea of a closed loop design can also be seen in Medtronic's MiniMed 530G, a breakthrough combination glucose monitor and insulin pump dubbed as the "world's first wearable artificial pancreas."


MiniMed 530G. Source: Medtronic

MiniMed 530G's loop is easy to understand -- insulin is continuously injected until blood sugar levels drop below preset levels. When that happens, the glucose monitor part shuts off the pump for two hours. This could significantly improve the quality of lives for patients with type 1 diabetes, who need to continuously monitor their blood sugar levels with pinpricks throughout the day.

However, the MiniMed 530G is not a fully automatic artificial pancreas, which would ideally deliver insulin continuously according to fluctuating glucose levels.

To address that need, Johnson & Johnson's (NYSE:JNJ) Animas division and insulin pump maker DexCom are developing a new artificial pancreas that goes a step beyond Medtronic's device with a system that tries to keep blood sugar between a preset range by modifying insulin delivery accordingly.

For J&J, an artificial pancreas is a key way to beef up its diabetes portfolio -- which it has been growing on the medical device front with wireless glucose monitors from LifeScan, and on the pharmaceutical front with new drugs like Invokana.

The Foolish takeaway
In conclusion, Medtronic certainly deserves its spot as one of the smartest companies of 2013. Its innovations in remote patient monitoring and closed-loop systems definitely make it one of the most cutting-edge medical device makers today. More importantly, Medtronic's products continuously inspire other companies -- like St. Jude Medical, Boston Scientific, J&J, and DexCom -- to develop even more advanced devices.

Invest in the next wave of health care innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion dollar industry." And the technology behind it is poised to set off one of the most remarkable health care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential, and its ability to make life-changing medical solutions never thought possible. To learn how you can invest in this unbelievable new technology, click here now to see our free report.

Leo Sun has no position in any stocks mentioned. The Motley Fool recommends Google (C shares) and Johnson & Johnson. The Motley Fool owns shares of Google (C shares), Johnson & Johnson, and Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information